SG Americas Securities LLC Has $4.50 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

SG Americas Securities LLC grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 2,159.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 430,051 shares of the company's stock after acquiring an additional 411,015 shares during the period. SG Americas Securities LLC owned 0.38% of Dyne Therapeutics worth $4,498,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in Dyne Therapeutics during the fourth quarter valued at approximately $2,340,000. Schroder Investment Management Group raised its stake in shares of Dyne Therapeutics by 63.3% during the 4th quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after purchasing an additional 56,961 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Dyne Therapeutics by 54.5% in the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after buying an additional 13,677 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Dyne Therapeutics by 3.3% in the 4th quarter. Swiss National Bank now owns 108,600 shares of the company's stock valued at $2,559,000 after buying an additional 3,500 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Dyne Therapeutics by 7.7% in the fourth quarter. Northern Trust Corp now owns 777,013 shares of the company's stock valued at $18,306,000 after buying an additional 55,511 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Dyne Therapeutics Price Performance

DYN traded down $0.05 on Friday, hitting $14.41. 1,747,992 shares of the stock were exchanged, compared to its average volume of 1,678,868. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -4.05 and a beta of 1.17. The business has a 50-day moving average of $11.04 and a two-hundred day moving average of $15.33.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on DYN shares. Evercore ISI began coverage on shares of Dyne Therapeutics in a research report on Thursday, May 29th. They set an "outperform" rating and a $46.00 price target on the stock. Scotiabank assumed coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. Chardan Capital reiterated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Friday, May 9th. BMO Capital Markets assumed coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective for the company. Finally, HC Wainwright reduced their target price on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $44.93.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.